Attivio Helps Life Sciences Innovator Relay Technology Management Dramatically Cut Time to Market

Relay's Innovation Engine Solves Inefficiencies for Early Stage Drug Development Stakeholders

NEWTON, Mass., Dec. 5, 2011 /PRNewswire/ -- Attivio, Inc. announced today that it has been selected by Relay Technology Management to power a new platform that addresses the urgent need in the Life Sciences industry for stakeholders to capture, access, compare and track comprehensive scientific, clinical, transactional, and business information. The company's new Relay Innovation EngineTM removes inefficiencies and complexity for early stage drug development stakeholders from the biotech, pharmaceutical, technology transfer offices, and investment communities.

Relay's scope is unequaled, capturing a comprehensive body of scientific literature, including more than 20 million scientific publications, 8 million patents, 150,000 diseases, and 100,000 clinical trials.

In order to deliver on its vision, Relay's approach required a powerful technology that could efficiently aggregate, analyze and present structured data and unstructured content from diverse information sources, in a manner that would reliably scale, remain data type agnostic, and enable a superior end user experience.

Using AIE, Relay's SaaS solution was produced six months ahead of schedule -- requiring only a fraction of the development resources initially projected. For Relay users, similar efficiencies are anticipated. Industry norms suggest that professionals spend 80 percent of time locating relevant information and only 20 percent on actual research. Relay expects to reverse this inefficiency, dramatically reducing the time and effort involved with identifying and analyzing drug assets and targets, driving exponential innovation.

"The flexibility of Attivio's platform and their team's deep subject matter expertise helped us shorten our time-to-market by several orders of magnitude, an achievement we simply did not think was possible given the enormity of the technical challenge," said Brigham Hyde, Ph.D., Managing Director at Relay Technology Management. "Because of this, and through the integration of AIE with Relay's proprietary system architecture, ontologies, and quantification platform, the Relay Innovation Engine streamlines the time and complexity involved in sifting through large data sets and aggregating complex sources so that the life sciences community can perform value-added analysis on their business development decisions."

"Attivio is pleased to be deeply involved with the development of the Relay Innovation Engine, a meaningful solution for healthcare based on our Active Intelligence Engine," said Ali Riaz, Attivio President & CEO. "Companies are realizing the promise of unified information access, especially in critical areas where users need ease and speed of access to vast amounts of information in order to draw meaningful insight to support their decision making."

"The explosive growth of data, which is very often core to the value of today's SaaS/Cloud-based applications, is becoming an increasingly difficult issue for SaaS vendors to economically manage," according to Jeffrey M. Kaplan, Managing Director of THINKstrategies and founder of the Cloud Computing Showplace. "Attivio's UIA platform has become increasingly attractive to SaaS vendors because of the functional challenges of keeping pace with users' escalating data access requirements combined with the time-to-market mandates of intensifying competition within the SaaS/Cloud marketplace."

About Attivio

On-demand insight is critical to the success of any business, but the information that decisions and processes depend on is created and stored in many formats -- databases, spreadsheets, documents, emails, blogs and more. Attivio solves this long-standing problem of information isolation by integrating search, business intelligence and process automation capabilities to provide answers and intelligence -- not just data. With Attivio's Active Intelligence EngineTM (AIE), users retrieve and analyze all types of content and data with simple, search-style queries and via reports and executive dashboards.

AIE's dynamic approach to unified information access (UIA) features rapid development, true incremental scalability and a small footprint that can be easily embedded in other products and applications. Business and IT leaders, system integrators and independent software vendors partner with Attivio to address today's global business imperatives -- uncovering insights that drive innovation and reveal new opportunities, mitigating risk and containing cost. Please visit www.attivio.com for more information.

About Relay Technology Management, Inc.

Relay Technology Management (Relay) is a software analytics company focused on the life sciences industry. Relay's proprietary platform, The Relay Innovation Engine, aggregates scientific and market data in real-time and provides competitive business intelligence to Biotechnology & Pharmaceutical companies and University Technology Transfer Offices. The Relay Innovation Engine analytics platform enables identification of scientific and market trends in drug development in a way never before captured or visualized. Relay provides decision support and data interaction through a software-as-a-service platform to both business and research professionals in the life sciences industry. Relay was an award-winning finalist in the MassChallenge global competition. Relay is headquartered in Boston, Massachusetts.

Attivio and Active Intelligence Engine are trademarks of Attivio, Inc. All other names are trademarks of their respective companies.

Media Contact:
Steve Brownell
HB
[email protected]
781-893-0053

Attivio Contact
MaryAnne Sinville
[email protected]
857-226-5037

SOURCE Attivio, Inc.

 

Suggested Articles

The inclusion of Kupffer cells in in vitro hepatic cultures provides researchers with advanced tools for disease modeling and drug discovery.

A delay to Moderna's phase 3 COVID-19 study is part of a trend of tensions in the biotech’s relationship with the U.S. government, Reuters reported.

GlaxoSmithKline is continuing its strategy of giving out access to its vaccine platform as it adds Medicago to its growing partners list.